Medicilon Tumor Animal Model Debut

SAPA-DC 2017 Annual Scientific Seminar came to an end in Rockville, Maryland, USA on April 1, 2017.

During the meeting, Dr. Wang Jun, VP of Medicilon’s biology department, gave his speech on the “Animal Models in Drug Discovery on Immunotherapy at Medicilon”. He shared the latest developments of tumor animal model and part of technical data of Medicilon.

The conference gathered in the field of scientific research, clinical practice of medicine and policy supervision and other fields of experts and scholars on the scene of the most cutting-edge cancer immunotherapy. The 200 experts and scholars travelled from Maryland, Pennsylvania, New Jersey and China’s domestic pharmaceutical industry.

As an important business partner of the seminar, Dr. Wang Jun said, “It is a great honor to be able to introduce Medicilon’s entire animal model library, including the tumor animal model to the world’s regional pharmaceutical industry counterparts.

Medicilon attaches great importance to the pharmaceutical research and development technology to make sure that we master the cutting edge techniques of this part.

Medicilon has attended a lot of large academic exchange meeting such as SAPA. Collaboration and win-win are our mission as well as our vision of globalization.

Medicilon has a complete animal model library, including more than 200 kinds of tumor models and 50 kinds of disease models available for domestic and foreign customers.

On the more popular models in recent years, such as orthotropic transplantation model, humanized tumor transplantation model, genetically modified model and etc., Medicilon’s current level of technology for them is mature and stable.

Followings are the part of contents from Dr. Wang Jun speech:

Xenograft Models (cellular therapy)

Syngeneic Models Syngeneic Mouse model (efficacy study)

PD study FCM Data Analysis

FCM Phenotypic Analysis

FCM Panel Design

Pharmacology Services

other animal model at medicilon other animal models at medicilon

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客